Medicxi closes fifth fund to back ‘asset-centric' startups [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Medicxi, a European life sciences venture capital firm, said Friday it raised 500 million euros, or about $579 million, for its fifth investment fund. The firm will use the new bankroll to continue “asset-centric” investing, or building new companies around one or a few experimental “products” rather than broad drugmaking “platforms.” It'll also support other, existing biotechs that align with its focus, regardless of their stage of development. “Especially in times where generally in the market, capital is constrained, it helps us really focus on the stories that we believe have a higher chance of success of delivering products to patients,” said Medicxi partner and co-founder Giovanni Mariggi. The fundraise comes during a recent upswing in biotech venture funding. According to BioPharma Dive data, at least a dozen young biotechnology companies have raised more than $100 million in private funding since the beginning of October , part of a broader rally Mariggi attributes to l
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte (NASDAQ:PCVX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Vaxcyte's Chief Technical Ops Officer Sells Shares [Yahoo! Finance]Yahoo! Finance
- What Makes Vaxcyte (PCVX) So Attractive [Yahoo! Finance]Yahoo! Finance
- How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]Yahoo! Finance
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- PCVX's page on the SEC website